参考文献/References:
[1]Mills KT,Stefanescu A,He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol,2020,16(4):223-237.
[2]Nwabuo CC,Yano Y,Moreira HT,et al. Association between visit-to-visit blood pressure variability in early adulthood and myocardial structure and function in later life[J]. JAMA Cardiol,2020,5(7):795-801.
[3]Clark D 3rd,Nicholls SJ,St John J,et al. Visit-to-visit blood pressure variability,coronary atheroma progression,and clinical outcomes[J]. JAMA Cardiol,2019,4(5):437-443.
[4]Wang J,Shi X,Ma C,et al. Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease:a systematic review and meta-analysis[J]. J Hypertens,2017,35(1):10-17.
[5]Rosendaal FR,Cannegieter SC,van der Meer FJ,et al. A method to determine the optimal intensity of oral anticoagulant therapy[J]. Thromb Haemost,1993,69(3):236-239.
[6]Copplestone A,Roath S. Assessment of therapeutic control of anticoagulation[J]. Acta Haematol,1984,71(6):376-380.
[7]Danne T,Nimri R,Battelino T,et al. International consensus on use of continuous glucose monitoring[J]. Diabetes Care,2017,40(12):1631-1640.
[8]Tang X,Li S,Wang Y,et al. Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c[J]. Clin Chim Acta,2016,461:146-150.
[9]Beck RW,Bergenstal RM,Riddlesworth TD,et al. Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care,2019,42(3):400-405.
[10]Lu J,Ma X,Zhou J,et al. Association of time in range,as assessed by continuous glucose monitoring,with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care,2018,41(11):2370-2376.
[11]Lu J,Ma X,Shen Y,et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes[J]. Diabetes Technol Ther,2020,22(2):72-78.
[12]Doumas M,Tsioufis C,Fletcher R,et al. Time in therapeutic range,as a determinant of all-cause mortality in patients with hypertension[J]. J Am Heart Assoc,2017,6(11):e007131.
[13]Mancia G,Messerli F,Bakris G,et al. Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-Trandolapril study[J]. Hypertension ,2007,50(2):299-305.
[14]Chen K,Li C,Cornelius V,et al. Prognostic value of time in blood pressure target range among patients with heart?failure[J]. JACC Heart Fail,2022,10(6):369-379.
[15]Huxley RR,Lopez FL,Folsom AR,et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors:the Atherosclerosis Risk in Communities (ARIC) study[J]. Circulation,2011,123(14):1501-1508.
[16]Georgiopoulos G,Ntritsos G,Stamatelopoulos K,et al. The relationship between blood pressure and risk of atrial fibrillation:a Mendelian randomization study[J]. Eur J Prev Cardiol,2022,29(11):1494-1500.
[17]Soliman EZ,Rahman AF,Zhang ZM,et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation[J]. Hypertension,2020,75(6):1491-1496.
[18]Wang J,Jiang C,Li S,et al. Systolic blood pressure time in target range and incident atrial fibrillation in patients with hypertension:insights from the SPRINT trial[J]. Hypertension,2023,80(11):2306-2314.
[19]Fatani N,Dixon DL,van Tassell BW,et al. Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension[J]. J Am Coll Cardiol ,2021,77(10):1290-1299.
[20]Buckley LF,Baker WL,van Tassell BW,et al. Systolic blood pressure time in target range and major adverse kidney and cardiovascular events[J]. Hypertension,2023,80(2):305-313.
[21]Lin Z,Xiao Z,Chen W,et al. Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly:a Chinese veteran cohort study[J]. Eur J Prev Cardiol,2023,30(10):969-977.
[22]Ou YN,Tan CC,Shen XN,et al. Blood pressure and risks of cognitive impairment and dementia:a systematic review and meta-analysis of 209 prospective studies[J]. Hypertension ,2020,76(1):217-225.
[23]Peters R,Xu Y,Fitzgerald O,et al. Blood pressure lowering and prevention of dementia:an individual patient data meta-analysis[J]. Eur Heart J,2022,43(48):4980-4990.
[24]Ding J,Davis-Plourde KL,Sedaghat S,et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease:a meta-analysis of individual participant data from prospective cohort studies[J]. Lancet Neurol,2020,19(1):61-70.
[25]Li S,Jiang C,Wang Y,et al. Systolic blood pressure time in target range and cognitive outcomes:insights from the SPRINT MIND trial[J]. Hypertension,2023,80(8):1628-1636.
[26]de Havenon A,Anadani M,Prabhakaran S,et al. Increased blood pressure variability and the risk of probable dementia or mild cognitive impairment:a post hoc analysis of the SPRINT MIND trial[J]. J Am Heart Assoc,2021,10(18):e022206.
[27]Tikhonoff V,Zhang H,Richart T,et al. Blood pressure as a prognostic factor after acute stroke[J]. Lancet Neurol,2009,8(10):938-948.
[28]Kakaletsis N,Ntaios G,Milionis H,et al. Time of blood pressure in target range in acute ischemic stroke[J]. J Hypertens,2023,41(2):303-309.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(4):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(4):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(4):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]